Michigan Quarterly Review
The High Desert State Prison was supposed to save Susanville, CA, bringing jobs and money to the ailing town. And it did. But the costs were devastating.
It is March 1999. I’ve come home because the new High Desert State Prison needs teachers, and I need a job. At 8 a.m., I stop at the BP for the weekly paper: the first thing I notice is the place is full of prison guards. They’re buying cigarettes and gas, stirring whitener into coffee. Each is decked out in full uniform, army green suit and parka with the California Department of Corrections gold patch, shiny black boots, belt hung with batons and pepper spray. Most are young and beefy; all have the soldier hairdo, trim mustache, crisp creases these guys would pass any inspection.
Dr Mitchell Morris Named eMed Chief Operating Officer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Dr Mitchell Morris Named eMed Chief Operating Officer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(1)
XBiotech s New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer
AUSTIN, Texas, April 19, 2021 (GLOBE NEWSWIRE) XBiotech (NASDAQ: XBIT) announced today that the FDA has granted permission to commence clinical trials with its novel drug candidate for treating patients with pancreatic cancer. From 1992 to 2018 the death rate from pancreatic cancer steadily increased in the USA. It is now predicted that pancreatic cancer will claim 48,220 lives and be the 3
rd leading cause of cancer death in the USA in 2021 (National Cancer Institute s Surveillance, Epidemiology, and End Results (SEER) program).
Pancreatic cancer is typically identified at an advanced stage and treatment often includes surgery and aggressive chemotherapy. A current approved treatment involves combination chemotherapy including ONIVYDE and 5-fluorouracil, drugs that have significant toxicities and provide only modest response rates. XBiotech s new drug candidate (XB2001) specifically